Calendar · pharmadog

Sign In Subscribe

Week of May 15, 2023

12

May 15, 2023approval1185d agoINREBIC (FEDRATINIB HYDROCHLORIDE) — FDA approvalfedratinib

Sponsor: BRISTOL-MYERS. Form: CAPSULE. Route: ORAL

full page →fedratinib →fda approvals ↗

May 18, 2023approval1182d agoIMBRUVICA (IBRUTINIB) — FDA approvalAbbVie Inc.

Sponsor: PHARMACYCLICS LLC. Form: CAPSULE. Route: ORAL

full page →fda approvals ↗

May 18, 2023approval1182d agoMIEBO (PERFLUOROHEXYLOCTANE) — FDA approvalBausch & Lomb Corp

Sponsor: BAUSCH AND LOMB INC. Form: SOLUTION/DROPS. Route: OPHTHALMIC

full page →fda approvals ↗

May 18, 2023approval1182d agoIMBRUVICA (IBRUTINIB) — FDA approvalAbbVie Inc.

Sponsor: PHARMACYCLICS LLC. Form: TABLET. Route: ORAL

full page →fda approvals ↗

May 18, 2023approval1182d agoCYLTEZO (ADALIMUMAB-ADBM) — FDA approvalCYLTEZO

Sponsor: BOEHRINGER INGELHEIM. Form: INJECTABLE. Route: INJECTION

full page →CYLTEZO →fda approvals ↗

May 18, 2023approval1182d agoRINVOQ (UPADACITINIB) — FDA approvalupadacitinib tartrate ER

Sponsor: ABBVIE. Form: TABLET, EXTENDED RELEASE. Route: ORAL

full page →upadacitinib tartrate ER →fda approvals ↗

May 19, 2023approval1181d agoLEVETIRACETAM — FDA approvalAprecia Pharmaceuticals LLC

Sponsor: CHARTWELL MOLECULAR. Form: SOLUTION. Route: ORAL

full page →fda approvals ↗

May 19, 2023approval1181d agoLEVETIRACETAM — FDA approvalAprecia Pharmaceuticals LLC

Sponsor: CHARTWELL MOLECULAR. Form: SOLUTION. Route: ORAL

full page →fda approvals ↗

May 19, 2023approval1181d agoLEVETIRACETAM — FDA approvalAprecia Pharmaceuticals LLC

Sponsor: CHARTWELL MOLECULAR. Form: SOLUTION. Route: ORAL

full page →fda approvals ↗

May 19, 2023approval1181d agoLEVETIRACETAM — FDA approvalAprecia Pharmaceuticals LLC

Sponsor: CHARTWELL MOLECULAR. Form: SOLUTION. Route: ORAL

full page →fda approvals ↗

May 19, 2023approval1181d agoLEVETIRACETAM — FDA approvalAprecia Pharmaceuticals LLC

Sponsor: CHARTWELL MOLECULAR. Form: SOLUTION. Route: ORAL

full page →fda approvals ↗

May 19, 2023approval1181d agoEPKINLY (EPCORITAMAB-BYSP) — FDA approvalepcoritamab

Sponsor: GENMAB US, INC.. Form: INJECTABLE. Route: SUBCUTANEOUS

full page →epcoritamab →fda approvals ↗

Week of May 22, 2023

15

May 22, 2023approval1178d agoVIGPODER (VIGABATRIN) — FDA approvalPyros Pharmaceuticals Inc.

Sponsor: PYROS PHARMS. Form: FOR SOLUTION. Route: ORAL

full page →fda approvals ↗

May 22, 2023approval

Week of May 29, 2023

6

May 30, 2023approval1170d agoFINTEPLA (FENFLURAMINE HYDROCHLORIDE) — FDA approvalfenfluramine hydrochloride

Sponsor: UCB INC. Form: SOLUTION. Route: ORAL

full page →fenfluramine hydrochloride →fda approvals ↗

Jun 1, 2023approval

Week of Jun 5, 2023

17

Jun 5, 2023approval1164d agoDESIPRAMINE HYDROCHLORIDE — FDA approvalAmneal Pharmaceuticals, Inc.

Sponsor: AMNEAL PHARMS CO. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Jun 5, 2023approval

page 2 of 498